Healthy volunteers were enrolled in the study.
Conditions
Interventions
Intervention group: Intervention group: The first intervention group, which has been randomly and double-blindly selected, will take the Iranian Eltrombopag 50 mg tablets, and the second group will t
Sponsors
Actero Middle East Pharmaceutical Company
Eligibility
Sex/Gender
Male
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Good general health (liver, heart, and kidneys) Body mass index (18-28) Informed consent Age (18-60 years)
Exclusion criteria
Exclusion criteria: Addiction to alcohol, drugs and cigarettes Sensitivity to Eltrombopag Chronic disease treatment history
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Drug Plasma Concentration. Timepoint: 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72. Method of measurement: Liquid chromatography with dual mass spectrometer (LC/M?S/MS). | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug Plasma Concentration. Timepoint: 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72. Method of measurement: Liquid chromatography with dual mass spectrometer (LC/M?S/MS).;Drug Plasma Concentration. Timepoint: 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72. Method of measurement: Liquid chromatography with dual mass spectrometer (LC/M?S/MS). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSaeed Ghanbarzadeh
Tabriz University of Medical Sciences
Outcome results
None listed